Gleevec en es it fr

Gleevec Brand names, Gleevec Analogs

Gleevec Brand Names Mixture

  • No information avaliable

Gleevec Chemical_Formula


Gleevec RX_link

Gleevec fda sheet

Gleevec FDA

Gleevec msds (material safety sheet)

Gleevec Synthesis Reference

No information avaliable

Gleevec Molecular Weight

493.603 g/mol

Gleevec Melting Point

226 oC (mesylate salt)

Gleevec H2O Solubility

Very soluble in water at pH < 5.5 (mesylate salt)

Gleevec State


Gleevec LogP


Gleevec Dosage Forms

Capsule; Tablet

Gleevec Indication

For the treatment of newly diagnosed adult patients with Philadelphia chromosome positive chronic myeloid leukemia (CML). Also indicated for the treatment of pediatric patients with Ph+ chronic phase CML whose disease has recurred after stem cell transplant or who are resistant to interferon-alpha therapy. Also indicated with unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST).

Gleevec Pharmacology

Imatinib is an antineoplastic agent used to treat chronic myelogenous leukemia. Imatinib is a 2-phenylaminopyrimidine derivative that functions as a specific inhibitor of a number of tyrosine kinase enzymes. In chronic myelogenous leukemia, the Philadelphia chromosome leads to a fusion protein of Abl with Bcr (breakpoint cluster region), termed Bcr-Abl. As this is now a continuously active tyrosine kinase, Imatinib is used to decrease Bcr-Abl activity.

Gleevec Absorption

Imatinib is well absorbed with mean absolute bioavailability is 98% with maximum levels achieved within 2-4 hours of dosing

Gleevec side effects and Toxicity

Side effects include nausea, vomiting, diarrhea, loss of appetite, dry skin, hair loss, swelling (especially in the legs or around the eyes) and muscle cramps

Gleevec Patient Information

Gleevec Organisms Affected

Humans and other mammals